Abstract
Therapies for end-stage heart failure are limited by the donor shortage for heart transplantation and the shortcomings of left ventricular assist devices for destination therapy. Treatments that use stem cells to 'rebuild' the myocardium are, therefore, desirable. Such therapies use either stem cells derived from bone marrow or skeletal myoblasts. In clinical trials, however, neither method of administration has demonstrated an improvement in ventricular function. The MAGIC trial was a randomized, placebo-controlled study of high and low doses of skeletal myoblasts injected into the myocardium of patients with MI undergoing CABG surgery. No difference in left ventricular ejection fraction was noted in the cell-treated groups when compared with controls, although patients who received the high dose of myoblasts had a decrease in ventricular dimensions, raising the possibility of an antiremodeling effect. A higher incidence of ventricular arrhythmias was observed in the myoblast groups than in control patients.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cardiac regeneration: different cells same goal
Medical & Biological Engineering & Computing Open Access 16 April 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hunt SA et al. (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). Circulation 112: e154–e235
Rose EA et al. for the REMATCH Study Group (2001) Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345: 1435–1443
Meyer GP et al. (2006) Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 113: 1287–1294
Menasche P et al. (2008) The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117: 1189–1200
Hendrikx M et al. (2006) Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation 114 (Suppl I): I101–I107
Dib N et al. (2005) Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation 112: 1748–1755
Hagege AA et al. (2006) Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients. Circulation 114 (Suppl I): I108–I113
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Eisen, H. Skeletal myoblast transplantation: no MAGIC bullet for ischemic cardiomyopathy. Nat Rev Cardiol 5, 520–521 (2008). https://doi.org/10.1038/ncpcardio1299
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio1299
This article is cited by
-
Cardiac regeneration: different cells same goal
Medical & Biological Engineering & Computing (2011)